Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D Schouten, Ferry Lalezari, Dennis Peters, Willemijn S M E Theelen, Viktor H Koelzer, Kirsten D Mertz, Alfred Zippelius, Michel M van den Heuvel, Annegien Broeks, John B A G Haanen, Ton N Schumacher, Gerrit A Meijer, Egbert F Smit, Kim Monkhorst, Daniela S Thommen
PURPOSE: Durable clinical benefit to PD-1 blockade in NSCLC is currently limited to a small fraction of patients, underlining the need for predictive biomarkers. We recently identified a tumor-reactive tumor-infiltrating T lymphocyte (TIL) pool, termed PD-1T TILs, with predictive potential in NSCLC. Here, we examined PD-1T TILs as biomarker in NSCLC. EXPERIMENTAL DESIGN: PD-1T TILs were digitally quantified in120 baseline samples from advanced NSCLC patients treated with PD-1 blockade...
July 19, 2022: Clinical Cancer Research